Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2020-09-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
关于参加四川辖区上市公司投资者网上集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor collective reception day, where company executives will communicate with investors on topics such as governance, strategy, operations, financing plans, equity incentives, and sustainability. It is a notice of an event rather than a report or detailed financial disclosure. The document is short (535 characters) and does not contain financial statements or detailed data. It is not a report itself but an announcement of an investor communication event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-09-22 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2020年1-6月持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2020 Half-Year Continuous Supervision Follow-up Report" by a sponsoring institution for a listed company. It references the period January to June 2020 and contains detailed financial data, including revenue, net profit, cash flow, and R&D expenses for the half-year period. It also discusses risk factors, compliance, governance, and the use of raised funds. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a certification, but a full report with detailed financial and operational information for the half-year period. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-09-08 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2020 年半年度报告" which translates to "2020 Semi-Annual Report." It contains detailed financial data, including revenue, net profit, cash flow, earnings per share, and other financial metrics for the period January 1, 2020 to June 30, 2020. The document includes sections such as company overview, business summary, financial indicators, risk disclosures, and management statements. The length is substantial (15,000 characters) and it contains actual financial statements and analysis, not just an announcement or summary. The content and structure clearly indicate this is a comprehensive interim financial report for a half-year period, which fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-20 Chinese
2020年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through a public stock issuance by the company 成都先导药物开发股份有限公司. It includes specifics on the amount raised, usage of funds, management policies, investment projects, and compliance with regulatory requirements. The document is titled as a "专项报告" (special report) on the half-year usage of raised funds, covering the period ending June 30, 2020. It contains substantive financial data and detailed explanations about the capital raised and its deployment, which aligns with the category of Capital/Financing Update filings. It is not an announcement of a report publication, nor a full annual or interim report, but a focused update on fundraising and capital usage. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-08-20 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2020 半年度报告摘要' which translates to '2020 Half-Year Report Summary'. It contains detailed financial data for the first half of 2020, including assets, net profit, revenue, and other financial metrics. It also includes management discussion and analysis of business conditions and risks, typical of an interim or quarterly report. The document length is 4405 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or summary. The content includes financial figures, risk disclosures, and operational commentary for the half-year period, consistent with an Interim / Quarterly Report (IR). It is not a full annual report (10-K), nor a brief earnings release (ER), nor a regulatory announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-08-20 Chinese
2019年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2019 annual dividend distribution by the company 成都先导药物开发股份有限公司. It details the dividend per share, relevant dates for record, ex-dividend, and payment, the shareholders entitled to the dividend, tax withholding policies, and contact information for inquiries. It is not a full annual report or financial statement but a specific announcement about dividend distribution following the approval at the 2019 annual general meeting. This fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and details for shareholders. The document length is 2221 characters, consistent with a typical dividend announcement rather than a full report.
2020-06-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.